SCHEMBL433691

SCHEMBL433691

O=CC1(c2cccc(C(F)(F)F)c2)CCOCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.44
SLC6A4 P31645 3/20 0.44
SLC6A3 Q01959 2/20 0.44
SLC6A2 P23975 1/20 0.44
ALOX5 P09917 1/20 0.40
CCR2 P41597 1/20 0.40
MMP2 P08253 2/20 0.38
MMP13 P45452 2/20 0.38
OPRL1 P41146 1/20 0.38
HCAR3 P49019 1/20 0.38
HCAR2 Q8TDS4 1/20 0.38
MMP3 P08254 1/20 0.38
MMP9 P14780 1/20 0.38
MMP8 P22894 1/20 0.38
MMP14 P50281 1/20 0.38
KCNN4 O15554 1/20 0.37
OPRM1 P35372 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15862781 0.86 SLC6A4 (0.54) KDM1ASLC6A4SLC6A3SLC6A2CCR2
SCHEMBL14893684 0.86 SLC6A4 (0.50) KDM1ASLC6A4SLC6A3SLC6A2CCR2
SCHEMBL3517993 0.85 SLC6A4 (0.56) KDM1ASLC6A4SLC6A3SLC6A2CCR2
SCHEMBL15043628 0.83 SLC6A4 (0.45) KDM1ASLC6A4SLC6A3SLC6A2CCR2
SCHEMBL12473468 0.81 ALDH1A1 (0.43) KDM1ASLC6A4SLC6A3SLC6A2CCR2
SCHEMBL10178188 0.80 SLC6A4 (0.42) KDM1ASLC6A4SLC6A3SLC6A2CCR2
SCHEMBL12638726 0.77 ALOX5 (0.42) SLC6A4SLC6A3SLC6A2ALOX5HCAR3
SCHEMBL7811018 0.77 ALOX5 (0.42) ALOX5HCAR3HCAR2ALDH1A1
SCHEMBL9137028 0.77 ALOX5 (0.44) ALOX5OPRM1ALDH1A1
SCHEMBL433504 0.76 GAA (0.43) SLC6A4SLC6A3SLC6A2CCR2MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187437-B2 Substituted oxadiazole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2015-11-17 US disclosed
EP-2595969-B1 Substituted 3-phenyl-1,2,4-oxadiazole compounds BRISTOL MYERS SQUIBB CO (US) 2015-04-22 EP disclosed
US-8822510-B2 Substituted 3-phenyl-1,2,4-Oxadiazole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-02 US disclosed
EP-2619190-A1 SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS Bristol-Myers Squibb Company (US) 2013-07-31 EP disclosed
US-20130190361-A1 SUBSTITUTED OXADIAZOLE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2013-07-25 US disclosed
US-20130158001-A1 SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS BRISTOL-MYERS SQUBIB COMPANY 2013-06-20 US disclosed
EP-2595969-A1 SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS Bristol-Myers Squibb Company (US) 2013-05-29 EP disclosed
WO-2012040532-A1 SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-29 WO disclosed
WO-2012012477-A1 SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190361-A1 SUBSTITUTED OXADIAZOLE COMPOUNDS S1PR1, S1PR3, S1PR2 KDM1A 1980/4885SLC6A4 2567/4885SLC6A3 2098/4885
US-20130158001-A1 SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS S1PR1, S1PR3, S1PR2 KDM1A 2205/4885SLC6A4 2698/4885SLC6A3 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.